Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest ...

It’s a kind of control that no one has ever tried before in patients,” Tune’s chief scientific officer said Monday.

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution ...

Tune Therapeutics, an epigenome-editing company with origins at Duke University, has raised over $175 million in financing to advance a potential treatment for chronic hepatitis B and other diseases.

Investors clearly appreciate the song Tune Therapeutics is singing, handing over $175 million in series B funds as the ...

Tune Therapeutics’ co-founders, from left: Akira Matsuno, chief financial officer; Charles Gersbach; and Fyodor Urnov, who also serves on the startup’s scientific advisory board. (Tune Photos ...

Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution ...

The Durham ID building in downtown Durham, NC holds the North Carolina office of Tune Therapeutics, a growing biotech startup moving into trials. Brian Gordon Launched from a Duke University lab ...

The biotech plans to use the funding to advance clinical testing of an epigenetic silencing therapy it hopes could treat ...

In a bumper week for new biotech financings, debutante Kardigan ruled the roost with a $300 million first round that will ...